Cisplatin Resistance Associated with PARP Hyperactivation

Global cancer statistics

Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634

Mitochondrial membrane permeabilization in cell death

Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598

Molecular mechanisms of cisplatin resistance

Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions

D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819

Principles of cancer therapy: oncogene and non-oncogene addiction

Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells

Gajan, A., Sarma, A., Kim, S., Gurdziel, K., Wu, G. S., & Shekhar, M. P. V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.694793 · Cited by 20

Pt(IV)-PROTAC Complexes with Synergistic Antitumor Activity and Enhanced Membrane Permeability

Li, C.-X., Zou, Z.-R., Xu, S., Shi, J.-H., Zou, Y., Yan, M., & Zhang, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02909 · Cited by 20

PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials

Crafton, S., Bixel, K. L., & Hays, J. L. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.003 · Cited by 20

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

Werner, T. L., Sachdev, J. C., Swisher, E. M., Gutiérrez, M., Kittaneh, M., Stein, M. N., Xiong, H., Dunbar, M., Sullivan, D. M., Komarnitsky, P. B., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1488 · Cited by 19

The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity

Zhai, L., Li, S., Li, X., Li, H., Gu, F., Guo, X., Liu, F., Zhang, X., & Fu, L. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.11.004 · Cited by 18

Metabolic enzymes expressed by cancer cells impact the immune infiltrate

Stoll, G., Kremer, M., Bloy, N., Joseph, A., Castedo, M., Meurice, G., Klein, C., Galluzzi, L., Michels, J., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1571389 · Cited by 18

Possible mechanisms of cancer prevention by nicotinamide

Buqué, A., Bloy, N., Kroemer, G., & Galluzzi, L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15096 · Cited by 18

The amphibianPelophylax bergeri(Günther, 1986) testis poly(ADP-ribose)polymerases: relationship to endocrine disruptors during spermatogenesis

Maio, A. D., Trocchia, S., & Guerriero, G. (2014) · The European Zoological Journal · doi:10.1080/11250003.2014.902124 · Cited by 17

Metabolic features of cancer cells impact immunosurveillance

Joseph, A., Juncheng, P., Mondini, M., Labaied, N., Loi, M., Adam, J., Lafarge, A., Astesana, V., Obrist, F., Klein, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002362 · Cited by 16

Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer

Juncheng, P., Joseph, A., Lafarge, A., Martins, I., Obrist, F., Pol, J. G., Saavedra, E., Li, S., Sauvat, A., Cerrato, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004280 · Cited by 14

PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?

Levra, M. G., Olaussen, K. A., Novello, S., & Soria, J. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660765 · Cited by 15

Globospiramine from Voacanga globosa Exerts Robust Cytotoxic and Antiproliferative Activities on Cancer Cells by Inducing Caspase-Dependent Apoptosis in A549 Cells and Inhibiting MAPK14 (p38α): In Vitro and Computational Investigations

Manzano, J. A., Abellanosa, E. A., Aguilar, J. P. P., Brogi, S., Yen, C., Macabeo, A. P. G., & Austriaco, N. P. G. (2024) · Cells · doi:10.3390/cells13090772 · Cited by 14

KAT8 enhances the resistance of lung cancer cells to cisplatin by acetylation of PKM2

Li, Z., Lu, X., Zhang, J., Liu, T., Xu, M., Liu, S., & Liang, J. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001622 · Cited by 13

Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR–p53–NF-κB interactions

Kwon, M., Jang, H.-J., Kim, E. H., & Roh, J. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1235104 · Cited by 13

Poly(ADP–Ribose) Polymerase in Cervical Cancer Pathogenesis

Kotsopoulos, I. C., Kucukmetin, A., Mukhopadhyay, A., Lunec, J., & Curtin, N. J. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000654 · Cited by 13

Phase I study of veliparib in combination with gemcitabine

Stoller, R. G., Schmitz, J. C., Ding, F., Puhalla, S., Belani, C. P., Appleman, L. J., Lin, Y., Jiang, Y., Almokadem, S., Petro, D. P., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3409-3 · Cited by 13

ZIPK activates the IL‐6/STAT3 signaling pathway and promotes cisplatin resistance in gastric cancer cells

Fan, H., Ou, Q., Su, Q., Li, G., Deng, Z., Huang, X., & Bi, J. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13270 · Cited by 12

Modulating the DNA damage response to improve treatment response in cervical cancer

Cossar, L. H., Schache, A. G., Risk, J. M., Sacco, J. J., Jones, N. J., & Lord, R. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.03.002 · Cited by 12

NEIL3-mediated proteasomal degradation facilitates the repair of cisplatin-induced DNA damage in human cells

Aliyaskarova, U., Baiken, Y., Renaud, F., Couvé, S., Kisselev, A. F., Saparbaev, M. K., & Groisman, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-32186-3 · Cited by 10

Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)

Asano, H., Oda, K., Yoshihara, K., Ito, Y. M., Matsumura, N., Shimada, M., Watari, H., & Enomoto, T. (2022) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e55 · Cited by 11

Mass spectrometric discrimination of phospholipid patterns in cisplatin‐resistant and ‐sensitive cancer cells

Cadoni, E., Vaňhara, P., Valletta, E., Pinna, E., Vascellari, S., Caddeo, G., Isaia, F., Pani, A., Havel, J., & Pivetta, T. (2018) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8320 · Cited by 11

RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target

Pellarin, I., Belletti, B., & Baldassarre, G. (2020) · Medicinal Research Reviews · doi:10.1002/med.21741 · Cited by 10

The Role of PARP ‐1 and NF‐κB in Bile‐Induced DNA Damage and Oncogenic Profile in Hypopharyngeal Cells

Doukas, P. G., Vageli, D. P., & Judson, B. L. (2022) · The Laryngoscope · doi:10.1002/lary.30284 · Cited by 9

Poly(ADP-ribose) polymerase-1 and its ambiguous role in cellular life and death

Castedo, M., Lafarge, A., & Kroemer, G. (2023) · Cell Stress · doi:10.15698/cst2023.01.275 · Cited by 9

Responsive boronate ester lipid nanoparticles for enhanced delivery of veliparib and platinum (IV) prodrug in chemotherapy

Xiao, W., Geng, R., Bi, D., Sun, Y., Li, Z., Liu, Y., & Zhu, J. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.12.081 · Cited by 8

PARP Inhibitor Activates the Intrinsic Pathway of Apoptosis in Primary Lung Cancer Cells

Gangopadhyay, N. N., Luketich, J. D., Opest, A., Landreneau, R. J., & Schuchert, M. J. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.919303 · Cited by 8

ROS, Redox Regulation, and Anticancer Therapy

Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_9 · Cited by 7

HBXIP induces PARP1 via WTAP-mediated m6A modification and CEBPA-activated transcription in cisplatin resistance to hepatoma

Fu, X., Guo, S.-M., Ma, J., Ma, F.-Y., Wang, X. B., Tang, Y.-X., Li, Y., Zhang, W., & Ye, L. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01309-5 · Cited by 7

Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy

Haque, S., Yellu, M., Randhawa, J. S., & Sadraei, N. H. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s119537 · Cited by 7

New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors

Folk, W. P., Kumari, A., Iwasaki, T., Cassimere, E. K., Pyndiah, S., Martin, E., Homlar, K. C., & Sakamuro, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413324 · Cited by 7

BAG1, MGMT, FOXO1 , and DNAJA1 as potential drug targets for radiosensitizing cancer cell lines

Manunu, B., Serafin, A. M., & Akudugu, J. (2022) · International Journal of Radiation Biology · doi:10.1080/09553002.2022.2074164 · Cited by 6

ERα-dependent estrogen-TNFα signaling crosstalk increases cisplatin tolerance and migration of lung adenocarcinoma cells

Cheng, L., Lin, C., Chen, P., & Li, L. (2021) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2021.194715 · Cited by 6

Poly(ADP-ribose) polymerase1 (PARP1) and PARP inhibitors: New frontiers in cervical cancer

Rajawat, J., & Banerjee, M. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150943 · Cited by 5

Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges

Thein, K. Z., Thawani, R., & Kummar, S. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_9 · Cited by 5

Pyridoxal kinase and poly(ADP-ribose) affect the immune microenvironment of locally advanced cancers

Joseph, A., Juncheng, P., Michels, J., Kroemer, G., & Castedo, M. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950954 · Cited by 5

PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes

Gotoh, N., Minato, Y., Saitoh, T., Takahashi, N., Kasamatsu, T., Souma, K., Oda, T., Hoshino, T., Sakura, T., Ishizaki, T., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13393 · Cited by 5

Cervical cancer cell lines are sensitive to sub-erythemal UV exposure

Gu, W., Sun, S., Kahn, A., Dacus, D., Wendel, S. O., McMillan, N. A. J., & Wallace, N. A. (2018) · Gene · doi:10.1016/j.gene.2018.11.079 · Cited by 4

HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer

Citro, S., Ghiani, L., Doni, M., Miccolo, C., Tagliabue, M., Ansarin, M., & Chiocca, S. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107307 · Cited by 4

ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium

Rossi, G., Zullo, L., Cerbone, L., Coco, S., Longo, L., Tagliamento, M., Bello, M. G. D., Boccardo, S., Alama, A., & Genova, C. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1724283 · Cited by 4

PARP1 inhibition elicits immune responses against non-small cell lung cancer

Juncheng, P., Lafarge, A., Kroemer, G., & Castedo, M. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2111915 · Cited by 4

Discovery of amino acid-conjugated dimethylcardamonin analogues as potent anti-cervical cancer agents on SiHa cells targeting p53 signalling pathway

Khamto, N., Utama, K., Chawapun, P., Siriphong, S., Tateing, S., Duangdesh, S., Sangthong, P., Chomsri, N.-O., & Meepowpan, P. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117705 · Cited by 3

Silencing of TGIF sensitizes MDA‑MB‑231 human breast cancer cells to cisplatin‑induced apoptosis

Pan, T., Mao, T., Yang, H., Wang, H., & Wang, Y. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5780 · Cited by 3

TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer

Tang, L., Wang, M., Jiang, L., & Zeng, C. (2020) · Human Cell · doi:10.1007/s13577-020-00363-5 · Cited by 3

Cisplatin resistance coupled to enhanced sensitivity to metabolic interventions

Castedo, M., Obrist, F., & Kroemer, G. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1526004 · Cited by 3

Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025)

Ogasawara, A., Suzuki, S., Oda, K., Yunokawa, M., Yonemori, K., Mori, M., Kurosaki, A., Mori, M., Kitano, S., Shintani, D., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.04.007 · Cited by 2

In Vivo Level of Poly(ADP-ribose)

Miwa, M., Ida, C., Yamashita, S., Kouyama, K., Kuroda, Y., Eguchi, T., Ohta, N., Sato, T., Tsuda, M., & Tanaka, M. (2018) · Challenges · doi:10.3390/challe9010023 · Cited by 2

Nitric Oxide and Platinum-Derivative-Based Regimens for Cancer Treatment: From Preclinical Studies to Clinical Trials

Plenchette, S., Paul, C., & Bettaı̈eb, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811020-1.00006-5 · Cited by 2

A375 melanoma cells are sensitized to cisplatin-induced toxicity by a synthetic nitro-flavone derivative 2-(4-Nitrophenyl)-4H-chromen-4-one through inhibition of PARP1

Mitra, A., & Ghosh, R. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06600-w · Cited by 2

Place des inhibiteurs de PARP dans le traitement des cancers de l’endomètre et du col de l’utérus

Gac, M. L., Koual, M., Delanoy, N., Perkins, G., Nguyen-Xuan, H.-T., Blons, H., Frère‐Belda, M. L., Laurent‐Puig, P., Bentivegna, E., Durdux, C., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.09.011 · Cited by 2

Ternary copper( ii ) complexes of 1,10-phenanthroline and coumarin-based oxylacetates as pro-apoptotic UPR CHOP inducers

Masuri, S., Cabiddu, M. G., Moráň, L., Vesselá, T., Bartošík, M., Havel, J., Meloni, F., Cadoni, E., Vaňhara, P., & Pivetta, T. (2023) · New Journal of Chemistry · doi:10.1039/d3nj01317k · Cited by 2

Glucose transporter protein 1-targeted polymetallic coordination nanopolymer remodeled cisplatin-resistant microenvironment for enhanced chemotherapy of lung cancer

Zhang, W., Wang, X., Wang, P., Li, Q., Zhang, Y., Meng, X., Tian, G., Xiao, J., & Zhang, G. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.138424 · Cited by 1

Treatment of Pelvic Recurrence After Radiotherapy for Cervical Cancer

Song, Y., Zou, K., & Zou, L. (2025) · Cancers · doi:10.3390/cancers17243934 · Cited by 1

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion

Abdulkareem, N. M., Jiang, Y., Qi, Y., Liu, X., Zhang, X., Cai, S., Shao, J., Jeter-Jones, S. L., Rinkenbaugh, A. L., Cheng, C.-C., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2513742123 · Cited by 2

Metabolomic Profiling of Cultured Cancer Cells

Scoazec, M., Durand, S., Chery, A., Galluzzi, L., & Kroemer, G. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-801329-8.00008-8 · Cited by 1

Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma

Stoof, J., Andrieu, C., O’Connell, F., O'Sullivan, J. N., Lowery, M. A., & Walsh, N. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70816 · Cited by 2

Mitochondria in Cell Death Regulation

Vitale, I., Manic, G., Kroemer, G., & Galluzzi, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30046-3 · Cited by 1

Synthetic lethality in NSCLC cells: Interrogating the therapeutic potential of ATM deficiency

Elegbede, A. A. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27960

Expression and significance of PARP1 and PAR in triple-negative breast cancer

Li, H., Li, S., Zhai, L., & Fu, L. (2014) · Clinical Oncology and Cancer Research · doi:10.3969/j.issn.1000-8179.20141138

Enzymes in the Base Excision Repair Pathway as Targets for Small Molecule Mediated Therapeutics

Johnson, E. F., McCullough, A. K., & Lloyd, R. S. (2016) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814719735_0018

Targeted Therapy in Gynecological Malignancy

Zand, B., Westin, S. N., & Coleman, R. L. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch46

LINC01638 regulates miR-128/PDK1 to promotes cell proliferation and drug resistance in ovarian cancerPreprint

Ye, Y., & Wang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1509617/v2

LINC01638 regulates miR-128/PDK1 to promotes cell proliferation and drug resistance in ovarian cancerPreprint

Ye, Y., & Wang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1509617/v1

LINC01638 regulates miR-128/PDK1 to promotes cell proliferation and drug resistance in ovarian cancerPreprint

Ye, Y., & Wang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1509617/v3

Data from Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2023) · doi:10.1158/1078-0432.c.6526236

Data from Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2023) · doi:10.1158/1078-0432.c.6526236.v1

Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression

Kim, H. S., Kim, J.-K., Lee, J. H., Lee, Y., Lee, G. K., & Han, J. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00495

GATOR1 complex controls cisplatin sensitivity

Pan, Z.-R., Zhang, H.-X., Xiao, X., Brenner, C., & Dokudovskaya, S. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08392-4

K41-A enhances the antiproliferative efficacy of cisplatin in neuroblastoma by modulating apoptosis and autophagy

Şanlav, G., Özşengezer, S. K., Altun, Z. S., Bedіr, E., Aktaş, S., & Olgun, N. P. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf131

Découvrir des voies de signalisation dont l'inhibition potentialiserait les inhibiteurs de la Poly(ADP-Ribose) Polymérase dans les cancers du sein triple-négatifs

Jourdier, H. (2016) · doi:10.70675/01a236efz9719z491azafefz76380f2c7188

Caractérisation de nouveaux inhibiteurs de la kinase RIPK1 et de la nécroptose

Cann, F. L. (2017) · theses.fr (ABES) · doi:10.70675/14750b73za612z432ezbf7cz5b72ea09e2e5

Regulation of alternative splicing and polyadenylation by genotoxic anti-cancer agents

Tanaka, I. (2019) · theses.fr (ABES) · doi:10.70675/8177333az76a6z4204z808az958753142caf

Metabolic Roles of Acyl Coenzyme A-Binding Protein (ACBP)/Diazepam Binding Inhibitor (DBI)

Joseph, A. (2021) · theses.fr (ABES) · doi:10.70675/b045685ezd444z4b46zb0f9z0e726ceac466

Functional characterization of the GATOR1 complex in cisplatin resistance

Pan, Z. (2024) · theses.fr (ABES) · doi:10.70675/2ddcf286zc553z40fdzb34ez875b3288c76b

Novel captopril-valproic acid platinum(IV) hybrids with potent antiproliferative and antimetastatic activities targeting fibrosis and DNA-repair

Chen, Y. C., Feng, S., Liu, Z., Zhao, Y., Ji, C., & Wang, Q. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119066

BindingDB Entry 50043760: Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.

BindingDB (2014) · UC San Diego · doi:10.7270/q26h4jv0

Treatment options after tumor resistance: exploiting vulnerabilities from genome to tumor microenvironment

Li, J., Zhang, N., Piao, M., Zhao, J., Wang, Y., Li, C., Li, S., Huang, Z., Li, Y., Xun, Z., et al. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10392-5

Abstract 2152: PJ34-mediated PARP-1 enzymatic activity inhibition in cervical cancer modulates the cellular response to cisplatin

Mann, M., Chauhan, S. S., Kumar, S., Bhatla, N., Bakhshi, S., Gupta, R., Iqbal, S., & Kumar, L. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2152

MCL-1 dependency of cisplatin-resistant cancer cells

Michels, J., Obrist, F., Vitale, I., Lissa, D., Garcia, P., Behnam‐Motlagh, P., Kohno, K., Wu, G. S., Brenner, C., Castedo, M., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.029 · Cited by 68

Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells

Wang, Q., Xiong, J., Qiu, D., Zhao, X. B., Yan, D., Xu, W., Wang, Z., Chen, Q., Panday, S., Li, A., et al. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.08.001 · Cited by 31

Effect of PARP inhibitors on the proliferation inhibition by cisplatin in lung cancer cell lines

Liu, J. L., Sun, R., Li, W. H., Wang, Y., Cai, X. Y., & Jiang, W. (2012) · Zhonghua zhongliu fangzhi zazhi

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Michels, J., Vitale, I., Senovilla, L., Enot, D. P., Garcia, P., Lissa, D., Olaussen, K. A., Brenner, C., Soria, J., Castedo, M., et al. (2013) · Cell Cycle · doi:10.4161/cc.24034 · Cited by 78